Expression of water-soluble, ligand-binding concatameric extracellular domains of the human neuronal nicotinic receptor alpha4 and beta2 subunits in the yeast Pichia pastoris: glycosylation is not required for ligand binding.
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels that are responsible for cell communication via the neurotransmitter acetylcholine. The predominant nAChR subtype in the mammalian brain with a high affinity for nicotine is composed of α4 and β2 subunits. This nAChR subtype is responsible for addiction to nicotine and is thought to be implicated in Alzheimer and Parkinson diseases and therefore presents an important target for drug design. In an effort to obtain water-soluble, ligand-binding domains of the human α4β2 nAChR for structural studies, we expressed the extracellular domains (ECDs) of these subunits in the eukaryotic expression system Pichia pastoris. The wild-type ECDs and their mutants containing the more hydrophilic Cys-loop from the snail acetylcholine-binding protein (individually expressed or coexpressed) did not demonstrate any specific interaction with ligands. We then linked the mutated ECDs with the 24-amino acid peptide (AGS)(8) and observed that the β2-24-α4 ECD concatamer, but not the α4-24-β2 one, exhibited very satisfactory water solubility and ligand binding properties. The (125)I-epibatidine and [(3)H]nicotine bound to β2-24-α4 with dissociation constants (K(d)) of 0.38 and 19 nm, respectively, close to the published values for the intact α4β2 AChR. In addition, (125)I-epibatidine binding was blocked by nicotine, cytisine, acetylcholine, and carbamylcholine with inhibition constants (K(i)) of 20.64, 3.24, 242, and 2,254 nm, respectively. Interestingly, deglycosylation of the concatamer did not affect its ligand binding properties. Furthermore, the deglycosylated β2-24-α4 ECD existed mainly in monomeric form, thus forming an appropriate material for structural studies and possibly for pharmacological evaluation of novel α4β2 nAChR-specific agonists.
Department of Biochemistry, Hellenic Pasteur Institute, GR11521 Athens, Greece.
Christos
C
Stergiou
Paraskevi
P
Zisimopoulou
Socrates J
SJ
Tzartos
D015870:Gene Expression; D006801:Humans; D008024:Ligands; D009154:Mutation; D018722:Nicotinic Agonists / Q000737:chemistry; D010843:Pichia; D017434:Protein Structure, Tertiary; D011978:Receptors, Nicotinic / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D012995:Solubility
D008024:Ligands; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; D011994:Recombinant Proteins
J Pharmacol Exp Ther. 1997 Jul;282(1):7-13
9223534
Neuropsychopharmacology. 2000 Oct;23(4):351-64
10989262
Prog Neurobiol. 2000 May;61(1):75-111
10759066
Nat Rev Neurosci. 2002 Feb;3(2):102-14
11836518
Biochem Pharmacol. 2007 Oct 15;74(8):1092-101
17662959
Biochemistry. 1988 Apr 5;27(7):2346-57
3382627
J Biol Chem. 2005 Dec 2;280(48):39990-40002
16174636
J Neurosci Res. 1996 May 15;44(4):350-4
8739154
J Med Chem. 2002 Jul 18;45(15):3235-45
12109907
Biochim Biophys Acta. 2009 Feb;1794(2):355-66
19059502
Anal Biochem. 1989 Aug 1;180(2):195-204
2510544
J Pharmacol Exp Ther. 1996 Dec;279(3):1413-21
8968366
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Neuron. 1990 Nov;5(5):555-67
1699566
Mol Pharmacol. 2006 Aug;70(2):755-68
16720757
J Biol Chem. 2004 Sep 10;279(37):38287-93
15226316
J Pharmacol Exp Ther. 2004 Jul;310(1):98-107
15016836
Neuropharmacology. 2003 Sep;45(3):334-44
12871651
Biochim Biophys Acta. 2008 Sep;1784(9):1226-33
18502212
Brain. 2002 Jun;125(Pt 6):1177-95
12023309
Mol Pharmacol. 2003 Feb;63(2):332-41
12527804
Nature. 2008 Mar 20;452(7185):375-9
18322461
Mol Pharmacol. 2011 Jan;79(1):126-40
20923852
Vasc Health Risk Manag. 2008;4(4):837-45
19066000
Nature. 2001 May 17;411(6835):269-76
11357122
J Struct Biol. 1998;121(2):181-90
9615437
Anal Biochem. 1983 Jul 1;132(1):74-81
6312839
Annu Rev Pharmacol Toxicol. 2000;40:431-58
10836143
J Biol Chem. 2002 Jul 26;277(30):26980-6
12015305
Mol Pharmacol. 2006 Feb;69(2):558-63
16269534
Neuropharmacology. 1995 Jun;34(6):563-82
7566492
J Neurosci. 2003 Oct 8;23(27):9004-15
14534234
Eur J Pharmacol. 2000 Mar 30;393(1-3):215-22
10771016
J Mol Graph Model. 2008 Jun;26(8):1333-7
18329305
Trends Pharmacol Sci. 2007 May;28(5):229-35
17412429
J Biol Chem. 1998 Dec 4;273(49):32393-9
9829968
Trends Pharmacol Sci. 2006 Sep;27(9):482-91
16876883
Br J Pharmacol. 2009 Mar;156(6):970-81
19366353
Nature. 2009 Jan 1;457(7225):111-4
18987633
Nat Neurosci. 2007 Aug;10(8):953-62
17643119
Biochem Biophys Res Commun. 2008 May 2;369(2):648-53
18302933
Br J Pharmacol. 2000 Oct;131(4):729-39
11030722
J Neurochem. 2002 Aug;82(3):468-81
12153472
J Pharmacol Exp Ther. 1996 Jun;277(3):1383-96
8667201
J Mol Model. 2008 Oct;14(10):891-9
18607650